amgen

For US Healthcare Professionals

STAY UP TO DATE Explore Disease MANIFESTATION

You are now leaving www.IgG4Related.com

Amgen is not responsible for the content of external websites linked within www.IgG4Related.com. Do you want to continue?

Yes No

IgG4-RD flares may occur in the originally diagnosed organ and/or in other systems4-6

Within 3 years of any flare4-6

  • Up to 90% of patients with IgG4-RD will experience flare recurrence in any organ
  • 1 in 3 patients will experience flare recurrence in the same organ

Due to the often asymptomatic, silently progressive nature of IgG4-RD, patients may experience permanent structural damage and functional organ impairment. Awareness of how structural damage and organ impairment manifests is critically important to inform the timely diagnosis of IgG4-RD in your patients.1-3
disease-progression-card-1

Predicting the progression of IgG4-RD is an evolving science4,7
  • Several indicators can help predict the potential for severe disease, including visceral organ or multi-organ involvement, organ dysfunction, and a susceptibility for flare over a short period of time8,9
  • While some biomarkers may correlate with IgG4-RD activity, there is no singular biomarker that reliably detects or predicts disease activity in all patients4,7
disease-progression-card-2

There are 2 primary goals when addressing IgG4-RD9
  • Reduce short-term inflammation
  • Maintain remission over the long term
disease-progression-card-3

There are challenges in managing both acute symptoms and disease progression in IgG4-RD9,10
  • Corticosteroids are a common first-line treatment for IgG4-RD, but long-term use raises tolerability concerns9,11
  • Second-line treatment options after IgG4-RD relapse are limited to therapies that lack FDA approval.9,10

IgG4-RD, immunoglobulin G4-related disease.

LEARN ABOUT IgG4-RD DIAGNOSIS
  • References:

    1. Stone JH, Zen Y, Deshpande V. N Engl J Med. 2012;366:539-551. doi:10.1056/NEJMra1104650 2. Perugino CA, Stone JH. Nature. 2020;16:702-714. doi:10.1038/s41584-020-0500-7 3. Wallace ZS, Deshpande V, Mattoo H, et al. Arthritis Rheumatol. 2015;67(9):2466-2475. doi:10.1002/art.39205 4. Lanzillotta M, Mancuso G, Della-Torre E. BMJ. 2020;369:m1067. doi:10.1136/bmj.m1067 5. Lee HW, Moon S-H, Kim M-H, et al. J Gastroenterol. 2018;53:967-977. doi:10.1007/s00535-018-1434-6 6. Kalaitzakis E, Webster GJM. Aliment Pharmacol Ther. 2011;33(3):291-303. doi:10.1111/j.1365-2036.2010.04526.x 7. Abraham M, Khoshroshahi A. Expert Rev Clin Immunol. 2017;13(9):867-875. doi:10.1080/1744666X.2017.1354698 8. Umehara H, Okazaki K, Kawa S, et al. Mod Rheumatol. 2021;31(3):529-533. doi:10.1080/14397595.2020.1859710 9. Khosroshahi A, Wallace ZS, Crowe JL, et al. Arthritis Rheumatol. 2015;67(7):1688-1699. doi:10.1002/art.39132 10. Tanaka Y, Stone JH. Mod Rheumatol. 2023;33(2):229-236. doi:10.1093/mr/roac141 11. Strehl C, Ehlers L, Gaber T, et al. Front Immunol. 2019;10:1744. doi:10.3389/fimmu.2019.01744